Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $467000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 16.75% year-over-year to $467000.0, compared with a TTM value of $1.6 million through Dec 2025, down 8.32%, and an annual FY2025 reading of $1.6 million, down 8.32% over the prior year.
  • Depreciation & Amortization (CF) was $467000.0 for Q4 2025 at Kiniksa Pharmaceuticals International, up from $384000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $717000.0 in Q2 2021 and bottomed at $312000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $517350.0, with a median of $516500.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 110.26% in 2022, then plummeted 33.83% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $668000.0 in 2021, then decreased by 9.88% to $602000.0 in 2022, then fell by 10.3% to $540000.0 in 2023, then dropped by 25.93% to $400000.0 in 2024, then rose by 16.75% to $467000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for KNSA at $467000.0 in Q4 2025, $384000.0 in Q3 2025, and $358000.0 in Q2 2025.